The purpose of this NIS is to gather data from the daily clinical practice of the Jakavi®-treatment in a broad patient population. In order to evaluate the direct effect of Jakavi®, only JAK inhibitor naive patients will be documented in the first study arm; patients pretreated with JAK inhibitors will be documented in the second study arm to evaluate the long-term efficacy of Jakavi® in this subpopulation.~The documentation of all patients is carried out prospectively and begins after the baseline visit. The medical decision on which therapeutic and diagnostic measures to take is made solely by the responsible physician. The observational period per patient is 36 months. The visit schedule after the baseline visit is set by the responsible physician according to standard clinical care, the clinical condition of the respective patients and the SmPC.
This is a prospective, two-arm, non-interventional study of JAKAVI® (Ruxolitinib) in patients with myelofibrosis